Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.48 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30616268 | 0.94 | PDGFRB (0.66) | PDGFRBPDGFRAKDM4EALDH1A1HPGD | |
| SCHEMBL28314031 | 0.93 | PDGFRB (0.57) | PDGFRBPDGFRAKDM4EALDH1A1HPGD | |
| SCHEMBL28313242 | 0.89 | PDGFRB (0.52) | PDGFRBPDGFRAKDM4EALDH1A1HPGD | |
| SCHEMBL23640270 | 0.88 | PDGFRB (0.66) | PDGFRBPDGFRAKDM4EALDH1A1HPGD | |
| SCHEMBL29535684 | 0.87 | PDGFRB (0.64) | PDGFRBPDGFRAKDM4EALDH1A1HPGD | |
| SCHEMBL30448935 | 0.87 | PDGFRB (0.64) | PDGFRBPDGFRAKDM4EALDH1A1HPGD | |
| SCHEMBL23924017 | 0.87 | PDGFRB (0.64) | PDGFRBPDGFRAKDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL27894607 | 0.85 | PDGFRB (0.62) | PDGFRBPDGFRAKDM4EALDH1A1HPGD | |
| SCHEMBL29812587 | 0.84 | PDGFRB (0.60) | PDGFRBPDGFRAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL69942 | 0.82 | MCL1 (0.58) | PDGFRBPDGFRAKDM4EALDH1A1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-02-08 | — | — | US | claimed |
| CN-119841776-A | Tyrosine kinase inhibitors and uses thereof | 华上生技医药股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4452947-A1 | CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITOR | Exelixis, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118647603-A | Crystalline forms and salt forms of kinase inhibitors | 埃克塞里艾克西斯公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-113939503-B | Crystalline salt forms of kinase inhibitors | 埃克塞里艾克西斯公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117820226-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117624045-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117603138-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-117402114-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-111757735-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023122739-A1 | CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITOR | EXELIXIS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-115872906-A | Levatinib impurity and preparation method thereof | 山东铂源药业股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3976587-A1 | CRYSTALLINE SALT FORMS OF A KINASE INHIBITOR | Exelixis, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, MAP3K1 | PDGFRB 327/4885PDGFRA 564/4885KDM4E 2704/4885 |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | PDGFRB 327/4885PDGFRA 564/4885KDM4E 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.